tiprankstipranks
Trending News
More News >
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Technical Analysis

Compare
168 Followers

Technical Sentiment

Overall Consensus
Buy
11Bullish
3Neutral
8Bearish
Technical Analysis Consensus
Neutral
4Bullish
3Neutral
3Bearish
Moving Average Consensus
Buy
7Bullish
0Neutral
5Bearish
Inhibikase Therapeutics’s (IKT) Moving Averages Convergence Divergence (MACD) indicator is -0.04, suggesting Inhibikase Therapeutics is a Sell.
Inhibikase Therapeutics’s (IKT) 20-Day exponential moving average is 2.06, while Inhibikase Therapeutics’s (IKT) share price is $2.11, making it a Buy.
Inhibikase Therapeutics’s (IKT) 50-Day exponential moving average is 2.19, while Inhibikase Therapeutics’s (IKT) share price is $2.11, making it a Sell.

Inhibikase Therapeutics (IKT) Pivot Points

Apr 27, 2025, 05:29 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
2.01
2.06
2.16
2.21
2.31
2.36
2.46
Fibonacci
2.06
2.12
2.15
2.21
2.27
2.30
2.36
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Inhibikase Therapeutics (IKT) Moving Averages

Apr 27, 2025, 05:29 PM
Period
Simple
Exponential
MA5
2.08Buy
2.10Buy
MA10
2.02Buy
2.05Buy
MA20
1.99Buy
2.06Buy
MA50
2.23Sell
2.19Sell
MA100
2.56Sell
2.28Sell
MA200
2.12Sell
2.05Buy
Inhibikase Therapeutics’s (IKT) 10-Day exponential moving average is 2.05, while Inhibikase Therapeutics’s (IKT) share price is $2.11, making it a Buy.
Inhibikase Therapeutics’s (IKT) 100-Day exponential moving average is 2.28, while Inhibikase Therapeutics’s (IKT) share price is $2.11, making it a Sell.
Inhibikase Therapeutics’s (IKT) stock price is $2.11 and Inhibikase Therapeutics’s (IKT) 50-day simple moving average is 2.23, creating a Sell signal.
Inhibikase Therapeutics’s (IKT) stock price is $2.11 and Inhibikase Therapeutics’s (IKT) 100-day simple moving average is 2.56, creating a Sell signal.
Inhibikase Therapeutics’s (IKT) stock price is $2.11 and Inhibikase Therapeutics’s (IKT) 200-day simple moving average is 2.12, creating a Sell signal.

Inhibikase Therapeutics (IKT) Technical Indicators

Apr 27, 2025, 05:29 PM
Name
Value
Implied Action
RSI (14)
50.89
Neutral
STOCH (9,6)
85.39
Sell
STOCHRSI (14)
90.11
Sell
MACD (12,26)
-0.04
Sell
ADX (14)
13.88
Buy
Williams %R
-20.83
Buy
CCI (14)
72.52
Neutral
ATR (14)
0.20
-
Ultimate Oscillator
67.99
Neutral
ROC
14.67
Buy
Inhibikase Therapeutics’s (IKT) Relative Strength Index (RSI) is 50.89, creating a Neutral signal.
Inhibikase Therapeutics’s (IKT) Trend Strength Indicator (ADX) is 13.88, creating a Buy signal.
Inhibikase Therapeutics’s (IKT) Commodity Channel Index (CCI) is 72.52, creating a Neutral signal.
Inhibikase Therapeutics’s (IKT) Price Rate of Change (ROC) is 14.67, creating a Buy signal.

FAQ

Is IKT a Buy, Hold, or Sell?
Based on IKT’s technical indicators, IKT is a Buy.
    What is IKT’s RSI (14)?
    IKT’s RSI (14) is 50.89, which suggests IKT is a Neutral.
      What is IKT’s MACD?
      IKT’s MACD is -0.04, which suggests IKT is a Sell.
        What is IKT’s 5-day moving average?
        IKT’s 5-day moving average is 2.08, which suggests IKT is a Buy.
          What is IKT’s 20-day moving average?
          IKT 20-day moving average is 1.99, which suggests IKT is a Buy.
            What is IKT’s 50-day moving average?
            IKT’s 50-day moving average is 2.23, which suggests IKT is a Sell.
              What is IKT’s 200-day moving average?
              IKT’s 200-day moving average is 2.12, which suggests IKT is a Sell.
                What is IKT’s Williams % R (14)?
                IKT’s Williams % R (14) is -20.83, which suggests IKT is a Buy.
                  What is IKT’s CCI (14)?
                  IKT’s CCI (14) is 72.52, which suggests IKT is a Neutral.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis